Advanced Malignant Tumors Clinical Trial
Official title:
A Multicenter, Open Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of LBL-033 in the Treatment of Patients With Advanced Malignant Tumors.
This trial is an open and multicenter phase I/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.
This is an open, multicenter Phase I/II clinical trial of LBL-033 in the treatment of patients with advanced malignant tumors，which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness. The trial is divided into 2 parts: Phase 1 and Phase 2 Phase I study: Dose-escalation and PK expansion.The PK expansion study will be judged on the basis of dose escalation data. Phase II study: Dose expansion included 4 cohorts that required patients with MUC16-positive malignancies.Blood samples will be collected from all subjects in this trial. Phase I and Phase II studies are expected to recruit 113-468 patients ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05082545 -
Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT04128085 -
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05229497 -
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06223841 -
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05728541 -
Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05354076 -
Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo
|
Phase 2 | |
| Recruiting |
NCT05868876 -
A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05991583 -
A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05396391 -
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05235542 -
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05110807 -
A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05214482 -
A Study of AK112 in Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05653284 -
A Study of AK130 in Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05223231 -
Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT05198817 -
A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients
|
Phase 1 | |
| Active, not recruiting |
NCT05193721 -
A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06226363 -
Phase I Study of LNF1901 in Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT06167486 -
SG2918 For Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT04980690 -
Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05877924 -
A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.
|
Phase 1 |